Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European OTC Shifts: BMS Eyes Selling French Business, Private Equity Controls Italy's Recordati

Executive Summary

Bristol-Myers Squibb weighs selling its UPSA French OTC business, conducting a strategic review to assess its growth potential. Milan-based Recordati, says it plans to grow its OTC business; the firm sold a 51.8% stake owned by the Recordati family to a consortium of private equity funds for $3.56bn.

You may also be interested in...



Recordati Founding Family Sells €3bn Stake As PE Digs Deeper Into Pharma

With private equity interest in the health space booming, CVC has taken a controlling stake in Recordati for €3.03bn, at a sharp discount to the Italian company’s share price. 

P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint

P&G’s planned acquisition of Merck KGaA’s consumer health care business will grow its consumer health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories.  CEO David Taylor frames the acquisition as another step in the firm's ongoing portfolio shakeup.

P&G Could Be Last Suitor Standing For Pfizer's Consumer Health Business

A spin-off still is an option for Pfizer, as is continuing to operate the unit as it currently does. But P&G's apparent interest and dearth of other OTC business buyers changes the outlook for both companies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel